|
|
||||||||

* Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; and
Cardiovascular Division, Soest City Hospital of Munster University Medical School, Soest, Germany
The present study investigated the effects of mibefradil, a novel T-type channel blocker, on ventricular function and intracellular Ca2+ handling in normal and hypertrophied rat myocardium. Ca2+ transient was measured with the bioluminescent protein, aequorin. Mibefradil (2 µM) produced nonsignificant changes in isometric contraction and peak systolic intracellular Ca2+ concentration ([Ca2+]i) in normal rat myocardium. Hypertrophied papillary muscles isolated from aortic-banded rats 10 weeks after operation demonstrated a prolonged duration of isometric contraction, as well as decreased amplitudes of developed tension and peak Ca2+ transient compared with the sham-operated group. Additionally, diastolic [Ca2+]i increased in hypertrophied rat myocardium. The positive inotropic effect of isoproterenol stimulation was blunted in hypertrophied muscles despite a large increase in Ca2+ transient amplitude. Afterglimmers and corresponding aftercontractions were provoked with isoproterenol (10-5 and 10-4 M) stimulation in 4 out of 16 hypertrophied muscles, but were eliminated in the presence of mibefradil (2 µM). In addition, hypertrophied muscles in the presence of mibefradil had a significant improvement of contractile response to isoproterenol stimulation and a reduced diastolic [Ca2+]I, although a mild decrease of peak Ca2+-transient was also shown. However, verapamil (2 µM) did not restore the inotropic and Ca2+ modulating effects of isoproterenol in hypertrophied myocardium. Mibefradil partly restores the positive inotropic response to ß-adrenergic stimulation in hypertrophied myocardium from aortic-banded rats, an effect that might be useful in hypertrophied myocardium with impaired [Ca2+]i homeostasis.
Key Words: hypertrophied myocardium intracellular Ca2+ mibefradil
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |